Moderna prepares global launch of its COVID-19 vaccine


WASHINGTON, Oct. 29 (Xinhua) -- American biotechnology company Moderna said on Thursday it is preparing for the launch of its COVID-19 vaccine candidate globally.

"We are actively preparing for the launch of mRNA-1273 and we have signed a number of supply agreements with governments around the world," said Moderna CEO Stephane Bancel in a statement.

In addition to the Phase 3 study of the COVID-19 vaccine mRNA-1273, which is fully enrolled, Moderna now has four programs in Phase 2 studies, according to Bancel.

"Moderna is committed to the highest data quality standards and rigorous scientific research as we continue to work with regulators to advance mRNA-1273," he said.

On Oct. 22, the Phase 3 study of mRNA-1273 completed enrollment of 30,000 participants with approximately 37 percent of participants from diverse communities.

The Phase 1 interim analysis of the vaccine, published in The New England Journal of Medicine on July 14, showed that mRNA-1273 was generally well-tolerated across all age groups and induced rapid and strong immune responses against SARS-CoV-2.

Article type: metered
User Type: anonymous web
User Status:
Campaign ID: 18
Cxense type: free
User access status: 3
   

Did you find this article insightful?

Yes
No

Next In World

Germany will review anti-virus curbs in early January, state premier says
EU's Barnier: Talks continue 'even on Sunday'
Austrians to face further 'massive restrictions' after lockdown - Kurz
France must review COVID-19 crowd limits on church attendance
Thai protesters challenge king's military command
Czech government to allow shops, restaurants to reopen from Dec. 3
UK concerned over Iran situation, awaiting full facts on scientist killing
At least three people killed by flooding in Sardinia
Elite runners brave Delhi race despite COVID-19 surge, pollution concerns
Singaporean gives birth to baby with COVID-19 antibodies - report

Stories You'll Enjoy